ProCE Banner Activity

BICSTaR: BIC/FTC/TAF Effectiveness and Safety by Demographics and Baseline Characteristics at 24 Mo

Slideset Download
Conference Coverage

Investigators state that data support effectiveness, safety, and persistence of BIC/FTC/TAF in treatment-naive and treatment-experienced PWH with a high prevalence of comorbidities at baseline.

Released: November 07, 2022

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare